Close Menu

NEW YORK – Biocept said today that it received a notice from Nasdaq last week that it has failed to comply with a minimum bid price rule, which requires that companies listed on the Nasdaq Capital Market maintain a minimum closing bid price of at least $1.00 per share. As a result, it could face delisting action.

The firm has a 180 calendar-day grace period to regain compliance, by maintaining a minimum closing bid price for its stock of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar-day grace period.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.